• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Advocacy Groups Voice Concerns Over Bharat’s Vaccine Study

Advocacy Groups Voice Concerns Over Bharat’s Vaccine Study

January 18, 2021

Patient advocacy groups in India are claiming that Bharat Biotech failed to ensure trial participants clearly understood their role in a study of the company’s Covaxin COVID-19 vaccine.

The allegations, which were made in an open letter to the Indian government, cite issues in the company’s informed consent process and reimbursement program. Allegations from the patient advocacy groups state that the language in the informed consent forms for the vaccine trial was difficult to understand, especially for the mostly illiterate study population.

Given that most trial participants were of low income and at a low education level, the advocacy groups argued that trial participants may not have clearly understood the ethics behind the monetary reimbursement Bharat provided for participation.

Bharat has denied the allegations, noting that it had followed regulatory rules for participants in its phase 3 vaccine trial. Bharat also stated that the reimbursement of $10 to each trial participant was provided for expenses and was approved by all institutional ethics committees at all sites.

This latest controversy involving Bharat’s COVID-19 vaccine follows other criticisms of the company, including the fact that the Indian government issued an emergency-use approval for its vaccine before phase 3 trials were completed. Also, Bharat reportedly failed to disclose a viral pneumonitis event in a phase 1 trial of Covaxin. Instead, the adverse event was made public after reports about it leaked to the Indian media in November.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing